Ensifentrine-Ohtuvayre market price in 2025 and possibility of inclusion in medical insurance

Ensifentrine (trade name: Ohtuvayre) is a new dual-mechanism inhaled preparation that combines phosphodiesterase3/4 (PDE3/4) inhibitory effect, mainly used for acute exacerbation or chronic symptom management in patients with chronic obstructive pulmonary disease (COPD). The drug provides a new treatment option for COPD patients by dilating bronchial tubes, reducing inflammation and improving lung function, especially showing potential advantages in improving dyspnea and exercise tolerance.

As of2025, exefantine has not yet been officially launched in mainland China, so domestic hospitals and pharmacies cannot provide the drug. Due to the lack of long-term marketing and clinical data, exefantine has not been included in China's medical insurance directory. At present, if domestic patients need to use this drug, they can only obtain it through overseas purchase channels, and the price and access methods are restricted, resulting in a high financial burden.

In overseas markets, taking the US version as an example, Ohtuvayre specifications are 3mg/2.5mL, 60 dose/ box is sold in some pharmacies in Hong Kong for about 44,500 Hong Kong dollars/ box. The price is greatly affected by exchange rate fluctuations and differences in procurement channels. Compared with domestic drugs, the cost is significantly higher. Currently, there are no generic drugs available in overseas markets, so patients need to bear all drug costs themselves.

In the future, the inclusion of exefantine in China's medical insurance still needs to wait for the official launch and clinical evaluation results. When considering its use, patients should consider their doctor's assessment of their condition and drug efficacy, and plan their medication plan rationally. If you choose to purchase through overseas channels, you should ensure that the source of the medicine is formal, and it should be used and monitored under the guidance of a doctor, focusing on changes in respiratory function and possible adverse reactions to ensure safety and efficacy.

Reference materials:https://www.drugs.com/